Press Releases

Date	Summary	View
Toggle SummaryJan 21, 2020	RedHill Biopharma to Focus Commercial Efforts on Talicia® and Aemcolo®; Discontinuing Promotion of Legacy Products TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 21, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the ...	View HTML PDF Version
Toggle SummaryJan 02, 2020	RedHill Biopharma Regains Rights to its Proprietary Bowel Preparation RHB-106 TEL-AVIV, Israel and RALEIGH, N.C. , Jan. 02, 2020 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on commercialization and development of proprietary drugs for the ...	View HTML PDF Version
Toggle SummaryDec 17, 2019	RedHill Biopharma Initiates U.S. Promotion of Aemcolo® for Travelers’ Diarrhea Aemcolo ® (rifamycin) is a non-systemic antibiotic delivered directly to the site of non-invasive E. coli infection in the lower intestine Aemcolo ® is approved by the FDA for the treatment of travelers’ diarrhea, and is covered by a robust U.S. patent portfolio which, together with the U.S. ...	View HTML PDF Version
Toggle SummaryNov 19, 2019	RedHill Biopharma Reports Third Quarter 2019 Financial Results and Operational Highlights Key Highlights: U.S. FDA approval of Talicia ® for the treatment of Helicobacter pylori infection in adults Strategic partnership with Cosmo Pharmaceuticals , including investment of $36.3 million and exclusive rights to commercialize Aemcolo ® in the U.S. ...	View HTML PDF Version
Toggle SummaryNov 15, 2019	Dual-Listed RedHill Biopharma to Voluntarily Delist from Tel-Aviv Stock Exchange TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 15, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...	View HTML PDF Version
Toggle SummaryNov 13, 2019	RedHill Biopharma to Host Third Quarter 2019 Financial Results Conference Call on November 19, 2019 TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 13, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...	View HTML PDF Version
Toggle SummaryNov 12, 2019	RedHill Biopharma Announces Publication of RHB-102 Gastroenteritis Phase 3 Study Results in JAMA TEL-AVIV, Israel and RALEIGH, N.C. , Nov. 12, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for ...	View HTML PDF Version
Toggle SummaryNov 04, 2019	RedHill Biopharma Announces FDA Approval of Talicia® for Treatment of H. pylori in Adults RedHill plans to launch Talicia ® 1 in the U.S. in Q1/2020 for the treatment of H. pylori infection in adults, targeting more than two million patients estimated to be treated for H. pylori infection annually Talicia ® is the first and only FDA approved rifabutin-based H. ...	View HTML PDF Version
Toggle SummaryOct 29, 2019	RedHill Biopharma to Present at the BIO-Europe 2019 Conference TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 29, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version
Toggle SummaryOct 28, 2019	RedHill Biopharma to Present New Phase 3 Data on RHB-105 and RHB-104 at the American College of Gastroenterology 2019 Annual Meeting TEL-AVIV, Israel and RALEIGH, N.C. , Oct. 28, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL ) ( Tel-Aviv Stock Exchange : RDHL ) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily focused on the development and commercialization of clinical late-stage, ...	View HTML PDF Version

Subscribe to press releases